introduction Schizophrenia (SCH) is a common illness with lifetime risk of approximately one in 100 people. [1] The most likely age of onset for men is the mid-20s, while for women, it is in the early 30s. [2] Patients with SCH have higher rates of nicotine dependence through cigarette smoking (58%-88%), compared to the general population (about 25%), [3] and are often heavily dependent smokers who have great difficulty with smoking cessation. A number of potential interventions could improve outcomes for smoking cessation/reduction in patients with SCH. As individuals with SCH are at high risk for developing medical morbidity and mortality related to chronic smoking, helping patients with SCH to quit smoking is an important undertaking. [4] [5] [6] Nicotine gum has been shown to aid withdrawal and double success rates of smoking cessation. The use of nicotine polacrilex increases success rates within the range of 15%-30% in smoking cessation. In physician settings, the added benefits may be less; but nonetheless, the success rate can double [7] or patient use it wrongly. In most instances, patients do not use enough pieces of gum per day to relieve withdrawal and urge to smoke, or they stop the usage soon. [8] Background: Schizophrenia (SCH) is a common illness with lifetime risk of approximately one in 100 people. The most likely age of onset for men is the mid-20s, while for women, it is in the early 30s. Schizophrenic patients have higher rates of nicotine dependence. This study aims to compare the effectiveness of smoking cessation program using nicotine chewing gums and transdermal nicotine patches (TNPs) among schizophrenic patients in Chennai city. Methods: Participants were required to have a diagnosis of SCH in maintenance stage, who met diagnostic and statistical manual mental disorder-IV for SCH, to be at least 18 years old. The study participants were divided into two groups: Group A (10 participants) and Group B (10 participants). Nicotine chewing gums were administered to Group A participants, and TNPs were administered to Group B participants. Results: Among 20 participants, all the study participants were male with a mean age of 45.20 years. In this study, significant reduction on carbon monoxide level (mean difference -3.2 ± 0.78) and number of cigarettes (mean difference -4.11 ± 0.55) were noted on TNP trial (P < 0.64), and the significant difference on nicotine dependence was seen between groups (Group A and Group B) (P = 0.00). Conclusion: Even though the results of our study showed reduction in smoking, but not smoking cessation, still, a better understanding of the factors that lead to successful smoking cessation outcomes in smokers with SCH and other psychiatric disorders may lead to improvement in treatment plan.
Transdermal nicotine patches (TNPs) are used to help people stop smoking cigarettes and provide a source of nicotine that reduces the withdrawal symptoms experienced when smoking is stopped. Patch has several advantages: it delivers a steady supply of nicotine through the skin and into bloodstream for 18-24 h and does not give users the buzz they may feel from gums and lozenges. Further, it is the easiest form to stop using when the cessation program is completed. [9] The relationship between smoking and major depressive disorder has been more extensively studied and has important implications for success in smoking cessation [10] such that a history of major depressive disorder has been recognized as a poor prognostic sign for success in smoking cessation.
Few smoking cessation programs have been targeted toward psychiatric patients, particularly those with schizophrenic disorders. Addington et al. reported the use of a modified version of the 7-week behavioral program offered by the American Lung Association Freedom from smoking program. [11] This group therapy program emphasized psychoeducation, positive reinforcement, anxiety reduction, and adjunctive use of the nicotine transdermal patch; the endpoint smoking abstinence rate in Addington et al.'s study was 42%. [11, 12] Behavioral interventions such as contingency management may also improve smoking cessation outcomes in opiate-dependent smokers [13, 14] and in smokers with SCH. [15] Preliminary has suggested that only smoking cessation intervention (e.g., motivational enhancement therapy and relapse prevention therapy) may improve treatment outcomes and tolerability of treatment.
In the study reported here, our aim was to compare the effectiveness of smoking cessation program using nicotine chewing gums and TNPs among patients with SCH in Chennai city.
mEthods
Participants were required to have a diagnosis of SCH, based on the structured clinical interview by diagnostic and statistical manual mental disorder-IV (DSM-IV), to be at least 18 years old and who were on medication (bupropion -atypical antidepressant), to have smoked 5-15 cigarettes/day for at least the past year, to have the score of at least 6 on the Fagerstrom test for nicotine dependence (FTND), indicating high level of dependence, [16] and to indicate an interest in quitting smoking someday. Exclusion criteria included medical conditions (diabetes, hypertension, and psychological disorder other than SCH) contraindicating transdermal nicotine use, severe levels of disorientation of uncooperativeness, smokeless tobacco users, alcohol users under any cessation treatment, or positive breath alcohol level at any session. Procedures were approved by the Institutional Review Board of Ragas Dental College and Hospital, and written informed consent was obtained from all participants. Figure 1 and 2 represents the procedure performed in the study.
Baseline characteristics
Individual measures collected on the 1 st day of interventional program included demographic characteristic, smoking history (number of cigarettes per day), [17] and a 10-point scale that measures the motivation to quit smoking in Motivation to Stop Smoking scale. The current psychiatric symptom levels were measured using clinical global impression-SCH (CGI-SCH) scale. [18] Expired breath carbon monoxide (CO) was measured in ppm from a single breath using a CO monitor.
Procedure
Twenty male outpatients with diagnosis of SCH were recruited from a local outpatient SCH research foundation. Psychiatric diagnosis was confirmed by a board-certified psychiatrist. We adopted an international standard for diagnosed smokers using nicotine replacement therapy (NRT) in which 14 mg of nicotine patches were delivered in 24 h and 4 mg of nicotine chewing gums thrice a day were administered for 1 week. The study participants were divided into two groups: Group A (10 participants) and Group B (10 participants) [Flowchart 1]. Nicotine chewing gums were administered to Group A participants, and TNPs were administered to Group B participants. For nicotine chewing gums, participants were advised to taste the nicotine or feel a slight tingling in mouth and then stop chewing and place (park) the chewing gum between cheek and gum. When the tingling was almost gone (about 1 min), to start chewing again and repeat this procedure for about 30 min. Nicotine patch consisted of a thin and flexible paper medium sandwiched between clear double-sided tape (against the skin) and a flesh color bandage (on the outside). Only research staff applied and removed the patches. Participants were asked to look away while the patch was applied because some of the participants could feel the sense of patch applied, and the entire area was marked with permanent marker around the patch and arm.
Participants were instructed not to remove this patch unless they were experiencing unacceptable levels of side effects (e.g. dizziness, rashes, and dermatitis) from the patches. Participants were further instructed to notify the research staff before removing the patches and that removing the patches would necessitate their being withdrawn from the study.
Smoking abstinence was determined by self-reported cigarette use and verified with a CO level. Antipsychotic medications were maintained at the prestudy dose for the duration of the study; individuals who required a dose change for symptom stabilization or antipsychotic side effects were excluded from the analysis.
Smoking cessation was strongly encouraged; however, education of specific motivational techniques was not included in these sessions. Effectiveness of nicotine chewing gums and TNPs in smoking cessation was considered the outcome measure, i.e., 7-day point prevalence abstinence defined as self-reported reduction in number of cigarettes in the preceding 7 days plus an expired CO level of <5 ppm.
Statistical analysis
All analyses were conducted with International Business Machines (IBM), SPSS version 19 (Tamil Nadu, India) and the significance levels were all set at P = 0.05 (two-tailed). At first, the representativeness of the individuals entered into the analyses was tested. Correlation between subjective and objective smoking dependency among patients with SCH In this study, significant reduction on CO level (mean difference -3.2 ± 0.78) and number of cigarettes (mean difference -4.11 ± 0.55) were noted on TNP trial (P < 0.64),
Assessed for eligibility n = 20 (inmates who met the inclusion criteria) Group A (n = 10) received nicotine chewing gums Group B (n = 10) received transdermal nicotine patches Clinical examination, interview was carried out for participants and health education was given and the difference between groups (Group A and Group B) was significant (P = 0.00) [Tables 1-3 ]. Accordingly, our findings suggest that TNPs may be a clinically useful treatment for tobacco dependence in smokers with SCH and appear to be safe and well tolerated.
discussion
The major finding of this study was that schizophrenic individuals who were treated with TNPs had enhanced smoking reduction rates. Although relapse rates are considerably high in the general population after short-term discontinuation in smoking cessation treatment, the nicotinic receptor expression does not return to normal after smoking cessation in smokers without SCH. In SCH, nicotinic activity is abnormally low at baseline, which is increased by smoking or NRT, and is not expected to return to a normal baseline after smoking cessation.
At least, three studies have found that the atypical antipsychotic drug -clozapine may reduce smoking consumption in schizophrenic smokers. Our data on individuals grouped by nicotine transdermal patch suggest a differential effect for improving smoking abstinence rates in schizophrenic patients. [19] [20] [21] A study by Freedman et al. among patients who were receiving atypical antidepressant medications (bupropion 150 mg) treated with TNP was well tolerated and superior to antipsychotic medications with nicotine chewing gums.
However, it should be noted that given the low abstinence rates for nicotine chewing gums alone on short-term outcomes, the efficacy of the nicotine chewing gums employed in this study appears to be minimal, suggesting that the TNPs were an effective intervention.
Side effects of the combination were generally modest and included poor concentration, lightheadedness, muscle stiffness, activation, and insomnia. The increase in muscle stiffness may be well related to elevation of antipsychotic drug levels through deinduction of CYP 1A2 by smoking cessation [22] or inhibition of CYP2D6 by bupropion.
Finally, it should also be remembered that this study was conducted in stable outpatients. Acutely ill inpatients may respond differently to smoking abstinence and treated or untreated nicotine withdrawal, and generalizations of our findings to an acutely ill inpatient population should not be made.
This study failed to draw meaningful inferences on abstinence because no one had stopped smoking, but only smoking reduction was seen among the population.
conclusion
Although results of our study showed smoking reduction not a smoking cessation, still, a better understanding of the factors that lead to successful smoking cessation outcomes in smokers with SCH and other psychiatric disorders may lead to improved treatment for this subset of smokers, whose smoking habits are among the most refractory to conventional smoking cessation interventions. Hence, selection of the right intervention is the most important in the field of smoking cessation.
Ethical statement
This study was approved by Institutional Ethics Committee with reference number RDC-123 obtained on 28 th May 2018.
Declaration of Patient Consent
Patient consent statement was taken from each patient as per institutional ethics committee approval along with consent taken for participation in the study and publication of the scientific results / clinical information /image without revealing their identity, name or initials.The patient is aware that though confidentiality would be maintained anonymity cannot be guaranteed.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
rEfErEncEs

